Dr. med. Dirk Manski

 You are here: Urology Textbook > Drugs in Urology > Alpha-blocker > Terazosin

Alpha-Blocker (2/5): Terazosin

Review Literatur: (Chapple, 2004).

General Pharmacology of Terazosin

Please see section general pharmacology of alpha-blocker.

Mechanism of Action of Terazosin

Terazosin is a non-selective alpha1-blocker with a long elimination half-life.

Indications for Terazosin

Pharmacokinetics of Terazosin

Terazosin: Mechanism of Action

Postsynaptic alpha1-blockade leads to:

Side Effects of Terazosin

Contraindications of Terazosin

Urological Contraindications:

Conservative treatment of BPH is not indicated, if surgical treatment is imperative: chronic urinary retention with renal failure, recurrent hematuria due to prostatic enlargement, recurrent infections and bladder stones.

Cardiac Contraindications:

Hypotension, mechanical heart failure (valvular, pulmonary embolism, pericarditis), congestive heart failure.

Other contraindications:

Terazosin should be paused perioperatively for cataract surgery to prevent an intraoperative floppy iris syndrome.

Dosage of Terazosin

2–10~mg 0-0-1, titrate dosage after effect and side-effects, first week 1 mg, second week 2 mg, third week 5 mg, if necessary and possible fourth week 10 mg.

Index: 1–9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z


Chapple 2004 CHAPPLE, C. R.:
Pharmacological therapy of benign prostatic hyperplasia/lower urinary tract symptoms: an overview for the practising clinician.
In: BJU Int
94 (2004), Nr. 5, S. 738–44

  Deutsche Version: Terazosin